OBJECTIVEdTo examine the association of hemoglobin (Hb) A 1c variability with microvascular complications in the large cohort of subjects with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.
C ompelling evidence shows that long-term glycemic control, as expressed by hemoglobin (Hb) A 1c levels, is the main risk factor for the development of microvascular complications in type 1 (1) and type 2 diabetes (2), with risk rising exponentially as HbA 1c increases. Another risk factor related to hyperglycemia is variability of glycemic control that comprises "glucose variability" and "HbA 1c variability." Glucose variability relates to within-day fluctuations of glycemia, especially as a consequence of meals (3) , and may eventually reflect in increased HbA 1c levels. Conversely, HbA 1c variability relates to changes in glycemia over longer periods of time that result in change in HbA 1c from one visit to the next (4) .
Retrospective analyses of data from the Diabetes Control and Complications Trial (DCCT) have not confirmed that within-day glucose variability predicts the development of microvascular complications (5-7), although this was not a prespecified end point of the study. However, a prospective study specifically addressing this issue did not show any effect of within-day glucose fluctuations on cardiovascular events (8) . Conversely, retrospective analyses of the DCCT (9) and the Finnish Diabetic Nephropathy (FinnDiane) Study (10) risk factor for the development of diabetic retinopathy (DR) and nephropathy (DN) in individuals with type 1 diabetes. Moreover, HbA 1c variability was shown to be an independent variable that added to the effect of HbA 1c on the risk of microalbuminuria in adolescent patients with type 1 diabetes from the Oxford Regional Prospective Study and the Nephropathy Family Study (11) . Very recently, two prospective cohort studies from Japan and Taiwan, the Tsukuba Kawai Diabetes Registry 2 (12) and the Diabetes Management through an Integrated Delivery System project (13) , have shown that HbA 1c variability is associated with microalbuminuria, even after adjustment for known predictors of albuminuria, in 812 and 821 patients with type 2 diabetes, over a 4.3-year and a 6.2-year follow-up, respectively.
To further address this issue, we used the large cohort of Caucasian subjects with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study to assess whether the baseline status of DN and DR was independently associated with HbA 1c variability as assessed retrospectively from HbA 1c values obtained during the 2-year period preceding the enrollment. This study assessed DN by albuminuria and the estimated glomerular filtration rate (eGFR), and patients were stratified by chronic kidney disease (CKD) stage or phenotype.
RESEARCH DESIGN AND METHODS

Study cohort
We used the data collected at the baseline visit for the RIACE Italian Multicenter Study (registered with ClinicalTrials.gov, NCT00715481; URL http://clinicaltrials. gov/ct2/show/NCT00715481), an observational, prospective cohort study on the effect of eGFR on morbidity and mortality from cardiovascular disease (CVD) in type 2 diabetes.
The RIACE cohort consisted of 15,933 Caucasian patients with type 2 diabetes (defined by the American Diabetes Association criteria) consecutively attending 19 hospital-based diabetes clinics of the National Health Service throughout Italy (see Supplementary Data) in years [2007] [2008] . Exclusion criteria were dialysis or renal transplantation. The study protocol was reviewed by the locally appointed ethics boards. The quality and completeness of data were controlled, and 160 patients were excluded due to missing or implausible values. The remaining 15,773 subjects were subsequently analyzed. Multiple HbA 1c values (3-5, mean 6 SD: 4.52 6 0.76) serially measured during the 2-year period preceding the enrollment were available from nine centers for 8,290 patients (52.6% of the entire cohort). CVD risk factors and complications were determined as part of the baseline assessment. Measurements were undertaken from a standardized protocol across study centers.
CVD risk factors
All patients underwent a structured interview to collect information on age, smoking status, known diabetes duration, and current glucose-, blood pressure (BP)-, and lipid-lowering treatments as well as antiplatelet and anticoagulant therapy, with indication of the class of drug. Weight and height were assessed, with calculation of BMI. BP was measured with a sphygmomanometer after a 5-min rest. Triglycerides and total and HDL cholesterol were determined by standard analytical methods; LDL cholesterol was calculated by the Friedewald formula. Hypertension was defined as systolic BP $140 mmHg and/or diastolic BP $90 mmHg and/or antihypertensive treatment. Dyslipidemia was defined as high ($100 mg/dL) LDL cholesterol and/or lipid-lowering treatment.
Complications
The presence of CKD at baseline was assessed by albuminuria and serum creatinine. As previously reported in detail (14) , the albumin excretion rate (AER) was obtained from timed (24 h) urine collections or calculated from the albuminto-creatinine ratio in early-morning, firstvoided urine samples, in the absence of symptoms and signs of urinary tract infection or other interfering clinical conditions. Albuminuria was measured in one to three fresh urine samples for each patient by immunonephelometry or immunoturbidimetry, and the geometric mean was used for analysis in case of multiple measurements. In subjects with multiple measurements (4,062 with at least two and 2,310 with three values), the concordance rate between the first value and the geometric mean was .90% for all classes of albuminuria (14) . As an external quality control of urinary albumin assays, 50 samples from each center were reanalyzed at the reference laboratory using the immunonephelometry method to verify that the coefficients of variation between the peripheral and the central values were ,15% at least in the relevant clinical range of 15-500 mg/L, which was the case for 94% of samples (14) . Patients were then assigned to one of the following categories of albuminuria (mg/24 h): normoalbuminuria (AER ,30), microalbuminuria (AER 30-299), or macroalbuminuria (AER $300).
Serum (and urine) creatinine was measured by the modified Jaffe method. One to three measurements were obtained for each patient, and eGFR was calculated by the four-variable Modification of Diet in Renal Disease study equation (15) , using the mean serum creatinine value in case of multiple measures, as reported in previous publications (14, 16, 17 (18) . Patients assigned to CKD stages (and GFR classes) 4 and 5 were pooled. As previously reported (17) , CKD patients were further classified as having one of the following CKD phenotypes: albuminuria alone (stages 1-2 CKD), reduced eGFR alone (stage $3 CKD without albuminuria), or both (stage $3 CKD with albuminuria).
The presence of DR at baseline was assessed by dilated funduscopy. In each center, an expert ophthalmologist was asked to complete a standardized report form and to classify DR as absent, mild, moderate, or severe nonproliferative DR (NPDR), proliferative DR (PDR), and maculopathy, according to the Global Diabetic Retinopathy Project Group (19) . Patients were classified based on the actual fundus appearance or the retinal disease condition that had eventually required a previous photocoagulation or surgical treatment. On the basis of the worst eye, patients with NPDR of mild (microaneurysms only) or moderate (microaneurysms and other microvascular lesions) degree were classified as having nonadvanced DR, whereas those with severe NPDR or pre-PDR (i.e., microaneurysms/hemorrhages in four quadrants, or venous beadings in two quadrants, or intraretinal microvascular abnormalities in one quadrant), PDR (i.e., neovascularization from the disc or from elsewhere, vitreous hemorrhages, or tractional retinal detachment), maculopathy (retinal thickening or hard exudates distant from, approaching, or involving the center of the macula), or blindness (if less than 1/10 normal vision or 20/200 on the Snellen test) were grouped into the advanced DR category (20) .
Prevalent CVD at baseline was assessed from medical history by recording previously documented major acute CVD events, including myocardial infarction, stroke, foot ulcer or gangrene, amputation, coronary, carotid, and lower limb revascularization, and surgery for aortic aneurysm. CVD events were adjudicated based on hospital discharge records or specialist visits by an ad hoc committee in each center (21 All P values were two-sided, and a P value ,0.05 was considered statistically significant. Statistical analyses were performed using SPSS 13.0 software (SPSS Inc., Chicago, IL).
RESULTS
Patients' characteristics
Participants included in this analysis (i.e., those with 3 to 5 HbA 1c values) had a median (IQR) age and duration of diabetes at enrollment of 68 (61-74) and 14 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) years, respectively. The male-to-female ratio was 57:43. Likely due to longer disease duration, these subjects showed a worse CVD risk profile and a higher prevalence of any CVD event and were more frequently receiving treatment with glucose-, lipid-, and BP-lowering drugs than those excluded from the analysis due to unavailability of serial HbA 1c measurements (Supplementary Table 1 Table 2 ) and also with HbA 1c -SD quartiles (Supplementary Table 3 ).
Average HbA 1c and HbA 1c variability Increasing HbA 1c -MEAN was associated with longer diabetes duration and a more adverse CVD risk profile, and subjects were more frequently taking insulin alone or combined with an oral hypoglycemic agent, taking lipid-lowering drugs, and receiving antihypertensive treatment (including inhibitors of the renin-angiotensin system). Prevalence of albuminuria (microand macroalbuminuria) and DR (nonadvanced and advanced) increased markedly across HbA 1c -MEAN quartiles. Rates of reduced eGFR (,60 mL/min/1.73m
2 ), stages 1-2 CKD, and stages 3-5 albuminuric CKD increased by 49, 68, and 88%, respectively, from the lowest to the highest HbA 1c -MEAN quartile, whereas the rate of stages 3-5 nonalbuminuric CKD did not change significantly (Supplementary Table 2 ).
Higher HbA 1c variability (i.e., higher HbA 1c -SD) was associated with younger age, lower age at diabetes diagnosis, shorter diabetes duration, higher HbA 1c and BMI values, and a more adverse lipid profile, with no differences in BP levels. Prevalence of micro-and macroalbuminuria, reduced eGFR, stages 1-2 CKD, stages 3-5 albuminuric CKD, and advanced DR increased progressively with increasing HbA 1c -SD, whereas that of stages 3-5 nonalbuminuric CKD and nonadvanced DR did not change (Supplementary Table 3 ). Findings were similar for HbA 1c -CV, suggesting that differences among HbA 1c -SD quartiles were not solely attributable to differences in absolute HbA 1c -MEAN values (data not shown).
In Table 1 , prevalence rates are given for HbA 1c -MEAN and HbA 1c -SD above and below the population median values. For micro-and macroalbuminuria, reduced eGFR, stages 1-2 CKD, stages 3-5 albuminuric CKD, and advanced DR, the highest prevalence rates were observed when HbA 1c -MEAN and HbA 1c -SD were above the median; these subjects also showed the worst CVD risk profile. Conversely, the lowest prevalence for the above microvascular end points was found when both measures were below the median. No differences among the four groups were observed for stages 3-5 nonalbuminuric CKD. Interestingly, patients above the median for HbA 1c -MEAN and below the median for HbA 1c -SD had similar prevalence rates of albuminuria, reduced eGFR, and CKD phenotypes as patients below the median for HbA 1c -MEAN and above the Concerning other DN markers and CKD phenotypes, although rates of macroalbuminuria, reduced eGFR, and stages 3-5 albuminuric CKD were also similar between subjects above the median for HbA 1c -MEAN and below the median for HbA 1c -SD and those vice versa, logistic regression analysis showed that only HbA 1c -SD was independently associated with macroalbuminuria and stages 3-5 albuminuric CKD, whereas neither HbA 1c -MEAN nor HbA 1c -SD correlated with reduced eGFR or stages 3-5 nonalbuminuric CKD, although the highest HbA 1c -SD quartiles did. Altogether, these results suggest that HbA 1c variability might be even more important than average HbA 1c in conferring overall DN risk; however, longitudinal studies are needed to clarify this issue. Moreover, these data confirm (and extend to HbA 1c variability) our previous observation that reduced eGFR and, particularly, the nonalbuminuric CKD phenotype, in which an eGFR ,60 mL/min/1.73 m 2 develops in the absence of albuminuria, are not related to glycemic control (17) . This further supports the concept that macroangiopathy, rather than microangiopathy, is the prevailing renal pathology underlying nonalbuminuric CKD (17) , which nowadays is the predominant form of renal impairment in subjects with type 2 diabetes (17, (22) (23) (24) . Concerning DR, our study showed that only the rate of advanced DR increased significantly with increasing HbA 1c variability and that no effect of HbA 1c -SD could be detected on nonadvanced or advanced DR when adjusting for HbA 1c -MEAN and other known predictors of DR. This is at variance with findings in subjects with type 1 diabetes showing that increasing HbA 1c variability adds to the risk of DR exceeding that predicted by average HbA 1c alone (9, 10) . This discrepancy has no obvious explanation, especially if we consider that, again in type 1 diabetes, a rapid improvement of glycemic control can lead to a short-term worsening of DR, followed by a net improvement in the long-term (25) glycemic exposure, such as diabetes duration and treatments. In addition to showing that the effect of HbA 1c variability (and of average HbA 1c ) on microvascular complications in not univocal, our study confirms the results of previous reports indicating that HbA 1c change from one visit to the next affects the risk of (albuminuric) DN (9) (10) (11) (12) (13) . In fact, although the ranges of HbA 1c -MEAN and HbA 1c -SD were different in all these studies, the effect of HbA 1c variability was at least as much as that of average HbA 1c , albeit not predominant, except in our study showing a higher impact of HbA 1c -SD on macroalbuminuria and to a lesser extent on reduced eGFR and the combination of the two abnormalities in stages 3-5 albuminuric CKD. This suggests that HbA 1c variability is a major risk factor for the development of DN, at least of the albuminuric forms, although the underlying mechanisms have not been clarified yet (4) .
One possible explanation is that even periods of sustained hyperglycemia are "remembered," thus conferring an increased risk of microvascular complications (26), and, hence, that the detrimental effect of HbA 1c variability may be mediated through the same mechanism underlying the "metabolic memory" phenomenon, including oxidative stress (27) . Indeed, in patients with type 2 diabetes, overproduction of reactive oxygen species was associated with short-term glycemic excursions rather than with sustained hyperglycemia (28) , although there are data showing a prooxidant effect of longer period of hyperglycemia (29, 30) .
Another possible mechanism is that, because the risk of microvascular complications increases exponentially as HbA 1c rises (2), subjects with higher HbA 1c variability would "accumulate" a surplus of risk Finally, the link between fluctuations of HbA 1c and risk of microvascular complications might relate to the fact that patients with a higher HbA 1c -SD are those with a worse CVD risk profile and a more intensive glucose-lowering treatment. However, multiple regression analyses showed that the association of HbA 1c -SD with microvascular and, particularly, DN parameters was independent of confounding factors, including the higher BMI and triglycerides and lower HDL cholesterol levels that characterize the metabolic syndrome, a condition associated with an increased risk of developing renal disease (31) .
Strengths of this study include the large size of the cohort, the completeness of data, the analysis of a contemporary dataset, the adjustment for treatments, and, as mentioned above, the concurrent analysis of DR and DN, the latter assessed as both albuminuria and reduced eGFR. The main limitation is the cross-sectional design for the assessment of DN and DR that did not allow us to examine the effect of HbA 1c variability on the development of microvascular complications in uncomplicated individuals, as in the studies of Sugawara et al. (12) and Hsu et al. (13) .
Another limitation might be that the RIACE participants who had serial (3-5) HbA 1c measures had a longer diabetes duration, a worse CVD risk profile, a higher prevalence of any CVD event, and a higher rate of treatment than those who did not and were therefore excluded from this analysis. However, virtually all subjects from the nine centers that made available these data had more than two HbA 1c measures, independently of their HbA 1c variability, although a selection bias cannot be ruled out conclusively.
Other possible limitations concerning HbA 1c values are that they were performed in each center as a part of the patient's standard care, with no prespecified intervals between HbA 1c measurements, and that the number of measures per individual varied from 3 to 5. However, noncentralized measurements did not affect intraindividual variability, intervals between measurements ranged from 6 to 9 months, and adj-HbA 1c -SD was used to account for difference in the number of measures. Furthermore, although the number of measurements was not as large as in the study of Sugawara et al. (12) and the period analyzed was not as long as in the study of Hsu et al. (13) , reanalyses of these surveys showed that using 3-month (i.e., 4-5) HbA 1c measurements (12) or a series of 2-year HbA 1c values (13) , as in our study, did not change the results. Finally, potential limitations concerning noncentralized assessment of DN and DR have been addressed in previous RIACE reports (14, 17, 20) .
In conclusion, in patients with type 2 diabetes, HbA 1c variability affects albuminuria and albuminuric CKD phenotypes independently of (or instead of) average HbA 1c , even after adjustment for known risk factors for microvascular complications. On the contrary, HbA 1c variability has no effects on DR, which is mainly dependent on HbA 1c .
